Teva, Sanofi to Deliver Inflammatory Bowel Disease Treatment

 Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi US (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.

https://www.biospace.com/article/releases/teva-completes-closing-of-exclusive-collaboration-deal-to-deliver-inflammatory-bowel-disease-treatment/